IHE's Pharma Bet Beat Broad Healthcare by 22.6 Points
A concentrated pharmaceutical ETF returned 50% against 27.4% for its broader healthcare sibling, which carries $3.9 billion in assets. Both fell on Sept. 8 as the Dow dropped 1.13%.
The iShares U.S. Pharmaceuticals ETF (IHE) returned 50% against 27.4% for the more diversified iShares U.S. Healthcare ETF (IYH), which holds $3.9 billion in assets, according to a Motley Fool comparison published Sept. 8, 2026.
Two iShares funds cover much of the same ground in American health care, and one of them has been paid far better for it. The iShares U.S. Pharmaceuticals ETF (IHE), a concentrated basket of drugmakers, delivered a 50% gain over the stretch it is measured against, while the iShares U.S. Healthcare ETF (IYH), which spreads its money across the whole sector, returned 27.4%. That is a gap of 22.6 percentage points between two funds that a casual buyer might treat as interchangeable.
The comparison was drawn by Motley Fool on Sept. 8. The interesting part is not that the narrower fund won. It is what an investor gave up to win with it, and whether the same trade is available going into 2026.
What separates a pharmaceuticals fund from a healthcare fund
Health care as an equity sector is not one business. It contains drug discovery, medical devices, hospital operators, insurers and pharmacy middlemen, and those pieces respond to different things. Insurers move on medical cost trends and government reimbursement rates. Device makers move on hospital capital spending and procedure volumes. Drugmakers move on clinical data, patent expiries and pricing policy.
A pharmaceuticals-only fund such as IHE takes just the drug slice. That is a deliberate bet that the pipeline and pricing story beats the rest of the sector. When it works, as it evidently has, the fund captures the full move without the drag of the parts that lagged. A broad fund such as IYH owns everything, which means it also owns whatever underperformed.
The 27.4% figure for IYH is not a bad outcome in isolation. It only looks poor next to a fund that nearly doubled it. That framing matters, because concentration works in both directions and the record of one window is a weak guide to the next.
Diversification, assets and the practical case for the broader fund
IYH carries $3.9 billion in assets. Size is not a performance argument, but it is a liquidity and durability argument. Bigger funds tend to trade with tighter bid-ask spreads, which matters to anyone who buys and sells in size rather than setting and forgetting, and they are less likely to be closed or merged away.
The diversification argument for IYH is straightforward. If drug pricing policy tightens, or a handful of large-cap patent cliffs arrive at once, a pharmaceuticals-only fund has nowhere to hide. A whole-sector fund at least owns insurers and device makers that may not be hit by the same event. The trade-off is that in a year when pharma leads, the broad fund dilutes exactly the exposure that is working.
Anyone comparing the two should look past the headline return at three things: the overlap in top holdings, the number of names each fund actually holds, and the weight of the largest positions. Two funds can share their biggest constituents and still behave differently, because a concentrated fund gives those shared names a much heavier weight. That weighting, more than the holdings list, explains a gap of this size.
Both funds gave ground on Sept. 8
The most recent session was unkind to health care on both routes. IHE last traded at 102.68, down 1.91% from a previous close of 104.68, with a day range of 102.16 to 103.22. IYH closed weaker still, last quoted at 70.66, off 2.40% from a prior close of 72.40 and ranging between 70.61 and 71.31. Currency designation for both quotes was not specified in the data feed. Both figures are as of the last trade on Sept. 8, 2026, at 20:00 GMT; markets were closed thereafter.
Notably, the broad fund fell harder than the concentrated one on the day, by 0.49 percentage points. That is a single session and proves nothing on its own, but it is a useful reminder that "diversified" does not mean "defensive" when the whole sector is being sold.
The wider tape was soft. The S&P 500 tracker (SPY) closed at $765.96, down 0.55%, against a previous close of $770.19. The Nasdaq 100 proxy (QQQ) was nearly flat at $718.36, down 0.08%. The Dow tracker (DIA) took the worst of it at $528.03, down 1.13% from $534.08. Health-care weakness of 2% or more against a benchmark down half a percent is a sector-specific move, not a market-wide one.
What decides the 2026 answer
Health-care weakness of 2% or more against a benchmark down half a percent is a sector-specific move, not a market-wide one.
The honest reading is that the choice depends on what an investor believes about the next twelve months rather than what happened in the last set. Three questions do most of the work.
- Is the pharma leadership cyclical or structural? If the drug complex is being repriced on a durable earnings shift, concentration keeps paying. If it was a rerating that has already happened, the broader fund is the safer place to sit.
- How much single-name risk is acceptable? A concentrated fund's top holdings can drive most of its outcome. One failed readout or one adverse pricing ruling lands with disproportionate force.
- What is the holding period? A multi-decade holder is generally better served by owning the whole sector and paying nothing in attention. A tactical allocator has more reason to take the narrow exposure and accept the volatility.
Cost belongs in the calculation too. Expense ratios on sector funds are typically higher than on broad-market index products, and the difference compounds. Both funds' current fee levels should be checked on the issuer's own fact sheet before any comparison of past returns is treated as decisive, since a return figure is stated after fees but says nothing about what fees will cost from here.
What to watch next
Three things will settle the argument faster than any backtest. First, drug pricing policy: any change to how government programs negotiate or cap prices hits IHE harder than IYH by construction. Second, managed-care margins, which drive the insurer weight inside the broad fund and were a large part of why it trailed or led in any given stretch. Third, flows. If assets keep concentrating in the broad $3.9 billion product while the narrow fund posts the better numbers, that tells you retail and advisory money is buying the diversification argument regardless of the scoreboard.
For now the record is what it is: 50% against 27.4%, with the concentrated fund holding up slightly better in the latest down session. Neither of those facts is a forecast.
Key facts
- IHE last close: 102.68, -1.91% (Sept. 8, 2026, 20:00 GMT)
- IYH last close: 70.66, -2.40% (Sept. 8, 2026, 20:00 GMT)
- Return comparison: IHE 50% vs IYH 27.4%
- IYH assets: $3.9 billion
Frequently asked questions
What is the difference between IHE and IYH?
IHE is the iShares U.S. Pharmaceuticals ETF, a concentrated fund holding drugmakers only. IYH is the iShares U.S. Healthcare ETF, which spreads exposure across the whole sector, including insurers, device makers and providers alongside pharmaceuticals. IHE returned 50% over the compared period against 27.4% for IYH, but with far more single-name and single-industry concentration risk.
How much has each fund returned?
IHE delivered a 50% gain and IYH delivered 27.4% over the period the two funds were compared on, a difference of 22.6 percentage points. Past return figures are stated after fund fees but say nothing about future costs or performance, and a single measurement window is a weak guide to the next one.
How large is the iShares U.S. Healthcare ETF?
IYH holds $3.9 billion in assets. Fund size is not a performance argument in itself, but larger funds generally trade with tighter bid-ask spreads, which reduces transaction costs for anyone dealing in size, and are less likely to be closed or merged into another product by the issuer.
How did both funds trade on Sept. 8, 2026?
IHE last traded at 102.68, down 1.91% from a previous close of 104.68, with a day range of 102.16 to 103.22. IYH closed at 70.66, down 2.40% from 72.40, ranging between 70.61 and 71.31. Both figures are as of the last trade at 20:00 GMT that day.
Did the broader market fall on the same day?
Yes, but less sharply. The S&P 500 tracker SPY closed at $765.96, down 0.55%. The Nasdaq 100 proxy QQQ was near flat at $718.36, down 0.08%. The Dow tracker DIA fell 1.13% to $528.03. Health-care declines of over 2% therefore reflected sector-specific selling rather than a general market slide.
Which fund is better positioned for 2026?
It depends on the investor's view and horizon. A concentrated pharmaceuticals fund keeps paying if drug-sector leadership proves durable, but is exposed to pricing policy changes and patent cliffs. The broader healthcare fund dilutes that upside while adding insurers and device makers. Long-term holders generally favor breadth; tactical allocators take the narrower exposure.
Sources
- Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026? — Motley Fool
Photo: Magda Ehlers · Pexels Licence — source
